These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26718251)

  • 1. Community Pharmacy Practice Barriers in Preventing Drug Misuse, Divergence and Overdose: A Focus Group Study.
    Leong C; Sareen J; Enns MW; Bolton J; Alessi-Severini S
    Healthc Q; 2015; 18(3):28-33. PubMed ID: 26718251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community Pharmacists' Perspectives on Dispensing Medications With the Potential for Misuse, Diversion, and Intentional Overdose: Results of a Province-Wide Survey of Community Pharmacists in Canada.
    Leong C; Alessi-Severini S; Sareen J; Enns MW; Bolton J
    Subst Use Misuse; 2016 Nov; 51(13):1724-30. PubMed ID: 27487323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Legal pot, lower opioid death rate.
    Minn Med; 2015 May; 98(5):7. PubMed ID: 26065172
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical behavior of Japanese community pharmacists for preventing prescription drug overdose.
    Shimane T; Matsumoto T; Wada K
    Psychiatry Clin Neurosci; 2015 Apr; 69(4):220-7. PubMed ID: 25112197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription drug abuse communication: A qualitative analysis of prescriber and pharmacist perceptions and behaviors.
    Hagemeier NE; Tudiver F; Brewster S; Hagy EJ; Hagaman A; Pack RP
    Res Social Adm Pharm; 2016; 12(6):937-948. PubMed ID: 26806859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician practices to prevent ADHD stimulant diversion and misuse.
    Colaneri N; Keim S; Adesman A
    J Subst Abuse Treat; 2017 Mar; 74():26-34. PubMed ID: 28132697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoting consistent use of prescription drug monitoring programs (PDMP) in outpatient pharmacies: Removing administrative barriers and increasing awareness of Rx drug abuse.
    Norwood CW; Wright ER
    Res Social Adm Pharm; 2016; 12(3):509-14. PubMed ID: 26329535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Pharmacist as Gatekeeper of Prescription Drug Abuse: Return to "Community Scientists"].
    Shimane T
    Yakugaku Zasshi; 2016; 136(1):79-87. PubMed ID: 26725672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prescription Monitoring Program in Massachusetts and Its Use in Dentistry.
    Keith DA
    J Mass Dent Soc; 2015; 64(3):18-20. PubMed ID: 26727811
    [No Abstract]   [Full Text] [Related]  

  • 10. Do no harm: the role of community pharmacists in regulating public access to prescription drugs in Saudi Arabia.
    Bahnassi A
    Int J Pharm Pract; 2016 Apr; 24(2):142-5. PubMed ID: 26383607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing Prescription Opioid Misuse, Abuse and Overdose in Dentistry.
    Bragg LD
    J Okla Dent Assoc; 2015; 106(3):35-6. PubMed ID: 26480585
    [No Abstract]   [Full Text] [Related]  

  • 12. Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities.
    Marshall BD; Green TC; Yedinak JL; Hadland SE
    Int J Drug Policy; 2016 May; 31():25-31. PubMed ID: 26919826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical strategies and perceptions from community pharmacists following their experiences with conducting pharmacy practice research: a qualitative content analysis.
    De Vera MA; Campbell NKJ; Chhina H; Galo JS; Marra C
    Int J Pharm Pract; 2018 Aug; 26(4):302-309. PubMed ID: 29071805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: Improving clinical decision-making and supporting a pharmacist's professional judgment.
    Norwood CW; Wright ER
    Res Social Adm Pharm; 2016; 12(2):257-66. PubMed ID: 26143489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New DEA rules expand options for controlled substance disposal.
    Peterson DM
    J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):22-6. PubMed ID: 25607591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers and facilitators to dispensing of intranasal naloxone by pharmacists.
    Bakhireva LN; Bautista A; Cano S; Shrestha S; Bachyrycz AM; Cruz TH
    Subst Abus; 2018; 39(3):331-341. PubMed ID: 29043922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal.
    Nielsen S; Menon N; Larney S; Farrell M; Degenhardt L
    Addiction; 2016 Dec; 111(12):2177-2186. PubMed ID: 27367125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Paradigm for Providers: Dentists and Pharmacists.
    Park T
    J Calif Dent Assoc; 2015 Nov; 43(11):669-71. PubMed ID: 26798884
    [No Abstract]   [Full Text] [Related]  

  • 20. Many states lagging in efforts to curb prescription drug misuse, says report.
    McCarthy M
    BMJ; 2013 Oct; 347():f6116. PubMed ID: 24114118
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.